Dr. Grigory Luchansky Coordinates a New Initiative in the Global Longevity Program
Dr. Grigory Luchansky, Senior Vice President of the International Congress of Industrialists and Entrepreneurs, is an investor and coordinator of the international program of developing the precision diagnostics and personalized medicine.
LONDON, May 16, 2019 /PRNewswire-PRWeb/ -- Dr. Grigory Luchansky (http://www.grigoryluchansky.org) is the initiator, sponsor and international coordinator of the UK-Kazakhstan program of development of the precision diagnostics and personalised therapies, including the anti-ageing medicine.
Dr. Luchansky facilitates the establishment of a medical research think-tank in the U.K., where top British and international scientists from Oxford University and other research centers will accumulate expert opinions on the most promising discoveries in anti-ageing medicine from around the globe (http://www.grigoryluchansky.com).
Based on the analysis and recommendations of the top British and international scientists, the companies that have developed the most promising and revolutionary medicines will be offered attractive opportunities for commercialization of new treatments in Kazakhstan and elsewhere in Asia.
Speaking about the economic benefits of this new program for Kazakhstan, Dr. Grigory Luchansky points: "This should boost the development of bio-technological industry in Kazakhstan and reduce this nation's dependence on the revenues generated by the mineral resources" (http://www.grigoryluchanskybusiness.com).
"Instead of legalising euthanasia, we need to develop precision diagnostics and personalised medicine therapies. We also need to legally speed up the availability of medical breakthroughs for the patients now considered as terminally ill", stresses Dr. Luchansky. "We need to give patients hope and a chance for cure. Some of them will be saved – and this is the main reason for developing the precision medicine and speeding up the test protocols by employing the latest biomedical and biotechnological tools for testing the new pharmaceutical products".
SOURCE Dr. Grigory Luchansky
Share this article